Irinotecan Hydrochloride Liposome Injection (II) Combined with Fluorouracil, Folinic Acid, Vermofenib and Cetuximab in First-line Treatment of BRAFV600E Mutated

Irinotecan Hydrochloride Liposome Injection (II) Combined with Fluorouracil, Folinic Acid, Vermofenib and Cetuximab in First-line Treatment of BRAFV600E Mutated Advanced Colorectal Cancer is a phase 2, randomised interventional study registered as NCT06603376 by Shanghai Changzheng Hospital, with a registry enrolment figure of 75 participants, started 2024-09-01 and due to reach its primary completion in 2026-08-31. Interventions recorded: FOLFIRI + Vemurafenib + Cetuximab; FOLFIRI ± Bevacizumab. Conditions listed: Colorectal Carcinoma. Primary outcome: Objective response rate. Colorectal eligibility wording from the registry: "* Patients with advanced colorectal adenocarcinoma confirmed by histology or cytology". Sites: China. No results are recorded here; the registry entry is the source.